Shares of Genocea Biosciences Inc. (NASDAQ:GNCA) traded down 2.9% during mid-day trading on Thursday . The stock traded as low as $5.24 and last traded at $5.29, with a volume of 141,066 shares trading hands. The stock had previously closed at $5.45.

Several analysts have issued reports on the company. Zacks Investment Research lowered Genocea Biosciences from a “buy” rating to a “hold” rating in a research note on Wednesday, July 6th. FBR & Co restated a “buy” rating on shares of Genocea Biosciences in a research note on Friday, June 10th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. Genocea Biosciences currently has an average rating of “Buy” and an average target price of $17.95.

The firm’s 50-day moving average is $4.49 and its 200 day moving average is $4.40. The company’s market capitalization is $146.77 million.

Genocea Biosciences (NASDAQ:GNCA) last posted its quarterly earnings results on Thursday, August 4th. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.05. On average, equities analysts anticipate that Genocea Biosciences Inc. will post ($1.63) EPS for the current year.

Genocea Biosciences, Inc is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company operates through business of developing and commercializing vaccines segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.